|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Current assets | ||||||||||||
| Cash | ||||||||||||
| Prepaid expenses | ||||||||||||
| Other receivables, net | ||||||||||||
| Total current assets | ||||||||||||
| Cash and cash equivalents held in Trust Account - restricted | ||||||||||||
| Total assets | ||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
| Current liabilities | ||||||||||||
| Accounts payable and accrued expenses | ||||||||||||
| Due to affiliate | ||||||||||||
| Total current liabilities | ||||||||||||
| Convertible note - due to Sponsor | ||||||||||||
| Promissory note | ||||||||||||
| Deferred underwriting fee | ||||||||||||
| Total liabilities | ||||||||||||
| Common stock, subject to possible redemption or tender, 12,674,622 and 13,544,944 shares at redemption value at June 30, 2018, and December 31, 2017, respectively | ||||||||||||
| Stockholders' equity: | ||||||||||||
| Preferred stock, $.0001 par value; 1,000,000 shares authorized; none issued and outstanding | ||||||||||||
| Common stock, $.0001 par value; 100,000,000 shares authorized; 6,533,785 and 6,477,668 shares issued and outstanding (excludes 12,674,622 and 13,544,944 shares subject to possible redemption) at June 30, 2018 and December 31, 2017, respectively | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total stockholders' equity | ||||||||||||
| Total liabilities and stockholders' equity |
Loading...
